erythromycin ethyl succinate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, produced by Streptomyces strains	1051	1264-62-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: erythromycin ethylsuccinate erythromycin ethyl succinate anamycin arpimycin eritrocina erythrocin ethyl succinate	A macrolide antibiotic, produced by Streptomyces erythreus. This compound is an ester of erythromycin base and succinic acid. It acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Molecular weight: 862.06 Formula: C43H75NO16 CLOGP: 3.25 LIPINSKI: 2 HAC: 17 HDO: 4 TPSA: 226.28 ALOGS: -3.76 ROTB: 14 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

erythromycin ethylsuccinate
erythromycin ethyl succinate
anamycin
arpimycin
eritrocina
erythrocin ethyl succinate

A macrolide antibiotic, produced by Streptomyces erythreus. This compound is an ester of erythromycin base and succinic acid. It acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.

Molecular weight: 862.06
Formula: C43H75NO16
CLOGP: 3.25
LIPINSKI: 2
HAC: 17
HDO: 4
TPSA: 226.28
ALOGS: -3.76
ROTB: 14

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
April 2, 1965	FDA	ARBOR PHARMS LLC

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	4580.36	12.44	2249	22029	308438	63156306
International normalised ratio fluctuation	227.91	12.44	69	24209	2409	63462335
Bloody discharge	176.81	12.44	51	24227	1500	63463244
Lyme disease	133.13	12.44	50	24228	3399	63461345
Abortion spontaneous	112.52	12.44	113	24165	47082	63417662
Seronegative arthritis	109.19	12.44	45	24233	3914	63460830
Exposure during pregnancy	68.26	12.44	170	24108	155377	63309367
Dislocation of vertebra	58.16	12.44	38	24240	8597	63456147
Anaphylactic reaction	57.49	12.44	96	24182	66004	63398740
Maternal exposure during pregnancy	53.28	12.44	195	24083	219867	63244877

Showing 1 to 10 of 91 entries

Previous1 2 3 4 5…10Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	475.82	15.35	278	8461	80251	34867941
Hyphaema	78.47	15.35	20	8719	567	34947625
Toxic epidermal necrolysis	75.77	15.35	54	8685	21592	34926600
Drug interaction	63.70	15.35	160	8579	225786	34722406
Product packaging issue	62.13	15.35	17	8722	637	34947555
Premature baby	51.01	15.35	41	8698	19592	34928600
Dystonia	44.87	15.35	30	8709	10815	34937377
Low birth weight baby	43.01	15.35	26	8713	7879	34940313
Rhabdomyolysis	41.91	15.35	67	8672	68096	34880096
Stupor	40.61	15.35	18	8721	2873	34945319

Showing 1 to 10 of 58 entries

Previous1 2 3 4 5 6Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	3172.79	12.04	1678	25483	297238	79419989
International normalised ratio fluctuation	217.28	12.04	70	27091	3384	79713843
Bloody discharge	175.38	12.04	52	27109	1901	79715326
Lyme disease	140.19	12.04	50	27111	3300	79713927
Maternal exposure during pregnancy	111.81	12.04	181	26980	136357	79580870
Drug interaction	97.78	12.04	337	26824	414846	79302381
Seronegative arthritis	96.92	12.04	42	27119	4650	79712577
Abortion spontaneous	96.10	12.04	80	27081	29427	79687800
Product packaging issue	73.53	12.04	24	27137	1209	79716018
Dislocation of vertebra	65.42	12.04	38	27123	7842	79709385

Showing 1 to 10 of 118 entries

Previous1 2 3 4 5…12Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
FDA CS	M0028311	Macrolides
FDA EPC	N0000175877	Macrolide
FDA EPC	N0000175935	Macrolide Antimicrobial
FDA PE	N0000009982	Decreased Sebaceous Gland Activity
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D011500	Protein Synthesis Inhibitors

Showing 1 to 9 of 9 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Meningitis	indication	7180009	DOID:9471
Bacterial septicemia	indication	10001005	DOID:0040085
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Bacterial pneumonia	indication	53084003	DOID:874
Urinary tract infectious disease	indication	68566005
Hepatic coma	indication	72836002	DOID:12550
Cholangitis	indication	82403002	DOID:9446
Infection of bone	indication	111253001
Infectious disease of abdomen	indication	128070006
Infectious disorder of joint	indication	363162000

Showing 1 to 10 of 24 entries

Previous1 2 3Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.61	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

Show entries

Search:

ID	Source
002755	NDDF
002757	NDDF
1014KSJ86F	UNII
12560	PUBCHEM_CID
12578001	SNOMEDCT_US
151373	RXNORM
30427009	SNOMEDCT_US
33314	MMSL
372694001	SNOMEDCT_US
39	INN_ID

Showing 1 to 10 of 30 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
E.E.S	HUMAN PRESCRIPTION DRUG LABEL	1	24338-134	GRANULE, FOR SUSPENSION	200 mg	ORAL	NDA	27 sections
E.E.S	HUMAN PRESCRIPTION DRUG LABEL	1	24338-134	GRANULE, FOR SUSPENSION	200 mg	ORAL	NDA	27 sections
E.E.S	HUMAN PRESCRIPTION DRUG LABEL	1	24338-136	GRANULE, FOR SUSPENSION	200 mg	ORAL	NDA	27 sections
E.E.S	HUMAN PRESCRIPTION DRUG LABEL	1	24338-136	GRANULE, FOR SUSPENSION	200 mg	ORAL	NDA	27 sections
E.E.S 400	HUMAN PRESCRIPTION DRUG LABEL	1	24338-100	TABLET	400 mg	ORAL	ANDA	27 sections
E.E.S 400	HUMAN PRESCRIPTION DRUG LABEL	1	24338-100	TABLET	400 mg	ORAL	ANDA	27 sections
Ery-Ped	HUMAN PRESCRIPTION DRUG LABEL	1	24338-130	SUSPENSION	400 mg	ORAL	NDA	27 sections
Ery-Ped	HUMAN PRESCRIPTION DRUG LABEL	1	24338-130	SUSPENSION	400 mg	ORAL	NDA	27 sections
Ery-Ped	HUMAN PRESCRIPTION DRUG LABEL	1	24338-132	SUSPENSION	200 mg	ORAL	NDA	27 sections
Ery-Ped	HUMAN PRESCRIPTION DRUG LABEL	1	24338-132	SUSPENSION	200 mg	ORAL	NDA	27 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next